Perioperative stroke: A perspective on challenges and opportunities for experimental treatment and diagnostic strategies

Xia Jin | Peiying Li | Dominik Michalski | Shen Li | Yueman Zhang | Jukka Jolkkonen | Lili Cui | Nadine Didwischus | Wei Xuan | Johannes Boltze

Abstract
Perioperative stroke is an ischemic or hemorrhagic cerebral event during or up to 30 days after surgery. It is a feared condition due to a relatively high incidence, difficulties in timely detection, and unfavorable outcome compared to spontaneously occurring stroke. Recent preclinical data suggest that specific pathophysiological mechanisms such as aggravated neuroinflammation contribute to the detrimental impact of perioperative stroke. Conventional treatment options are limited in the perioperative setting due to difficult diagnosis and medications affecting coagulation in may cases. On the contrary, the chance to anticipate cerebrovascular events at the time of surgery may pave the way for prevention strategies. This review provides an overview on perioperative stroke incidence, related problems, and underlying pathophysiological mechanisms. Based on this analysis, we assess experimental stroke treatments including neuroprotective approaches, cell therapies, and conditioning medicine strategies regarding their potential use in perioperative stroke. Interestingly, the specific aspects of perioperative stroke might enable a more effective application of experimental treatment strategies such as classical neuroprotection whereas others including cell therapies may be of limited use. We also discuss experimental diagnostic options for perioperative stroke augmenting classical clinical and imaging stroke diagnosis. While some experimental stroke treatments may have specific advantages in perioperative stroke, the paucity of established guidelines or multicenter clinical research initiatives currently limits their thorough investigation.

Keywords
experimental treatment, neuroprotection, perioperative stroke, stroke, translational research

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.
1 | INTRODUCTION

According to the Society for Neuroscience in Anesthesiology and Critical Care (SNACC) definitions, perioperative stroke (PS) describes an ischemic or hemorrhagic cerebral event during or up to 30 days after surgery. Non-modifiable risk factors for PS are higher age and female sex. The reasons for the higher PS risk in female patients are not well understood, but it is supposed that it may be related to faster progression of atherosclerosis after menopause. PS is most frequent after cardiac and neurosurgery, as well as after vascular thoracic and transplantation surgeries. The main etiology of ischemic PS seems to be embolic, but perfusion-related events are also of relevance. For instance, severe anesthesia-induced hypotension is associated with PS or can contribute to cerebral mal-perfusion in intra-interventional PS. Previously undiagnosed stenosis of a large brain-supplying artery may also play a role. The vast majority of PS, about 95%, is of ischemic nature. Consequently, this review will focus on ischemic events.

Perioperative stroke is a feared condition for numerous reasons. First, it is relatively frequent. In-depth analysis of more than 520,000 cases reported an overall incidence of 0.1% in patients undergoing non-cardiac surgery, which increased to 1.9% in high-risk populations. A large-scale retrospective investigation based on the US National Inpatient Sample involving over 10.5 million cases revealed a PS rate of 0.52% in patients undergoing non-cardiac surgery in 2004. Interestingly, the rate increased to 0.77% in 2013. Although these relative numbers may seem moderate, the large amounts of surgeries performed each year result in a considerable number of PS cases. Moreover, PS can be much more frequent in some populations of surgical patients, especially those who undergo cardiac surgery. In detail, PS rates of 8.8% were reported for mitral valve surgery, and up to 9.7% for double or triple valve surgery, respectively.

Second, PS can appear as a clinically silent event, sometimes referred to as covert PS, which is unrecognized on onset but detected later, for instance by means of brain imaging. Reasons for covert PS can be minor, subtle, or not properly classified symptoms. Moreover, the patient may be anesthetized or sedated during PS onset thus does not present obvious clinical symptoms. A recent multicenter clinical study revealed that covert PS appeared in 1 out of 14 (7.1%) non-cardiac surgical patients aged 65 or older. PS was also associated with a higher risk for cognitive decline 1 year after surgery.

Third, outcome after PS tends to be worse than in non-surgical (NS) stroke patients. In detail, mortality rates in PS patients can be up to eightfold higher than in comparable NS populations, with mortality rates of up to 26%. This illustrates the additional burden that PS inflicts on patients, their relatives, caretakers, and healthcare systems.

Common clinical reasons for the unfavorable outcome after PS are delayed diagnosis and intervention in case of covert PS, and potential difficulties in applying recanalization treatments (thrombolysis and thrombectomy) due to the recent surgery, medications that affect the coagulation system or the general condition of the patient. Recent SNACC guidelines recommend that early endovascular thrombectomy should be considered in PS patients to restore the cerebral blood flow. However, this therapeutic strategy requires clinical detection of the ischemic event and cerebral imaging including visualization of cerebral arteries in a narrow time window. PS patients also have an increased risk of hemorrhage independent of the cerebral event, which limits the use of intravenous thrombolysis markedly. The patients' general condition may further complicate early initiations of rehabilitative actions.

This complex clinical situation warrants assessment of experimental treatment options that are currently under development to augment established therapeutic strategies for stroke, regarding their potential applicability, limitations, and benefits in PS. This includes consideration of potential PS-specific pathophysiological mechanisms, related to the surgery or the underlying condition requiring it, which may contribute to the unfavorable PS outcome.

2 | DIFFERENCES IN PATHOPHYSIOLOGICAL MECHANISMS IN PERIOPERATIVE VERSUS SPONTANEOUSLY OCCURRING STROKE

Clinical and logistical necessities affecting PS management and contributing to the unfavorable PS outcome are well known. However, basic pathophysiological reasons for the unfavorable outcome are incompletely understood and subject to current research. A general limitation of these studies is that a specific animal model for PS does not exist. Instead, models of surgical interventions are combined with commonly used approaches to induce focal cerebral ischemia in an experimental subject. Nevertheless, preclinical studies using these PS models provide preliminary evidence for important pathophysiological differences between PS and NS stroke that may substantially contribute to inferior PS outcome. For instance, preclinical data suggest that the relatively high PS incidence in elderly and comorbid patients could be related to atherosclerotic plaque instability caused by perioperative stress. Plaque volume, stability, and signs for plaque rupture were investigated in apolipoprotein-E-deficient mice. Mice were fed a high cholesterol diet, inducing a well-accepted model to investigate plaque vulnerability. Some animals underwent laparotomy plus a major (about 20%) blood withdrawal, determined as the double hit paradigm. Plaque volumes were significantly increased in the double hit group, and more plaques were classified as bearing signs of rupture 3 days after inducing perioperative stress. Surgery or blood loss alone also increased plaque volumes, but inter-group differences were not statistically significant. Treatment with 80 mg/kg atorvastatin starting 3 days prior to surgery reduced cholesterol as well as plaque volume and instability.

Bone fracture models simulate a condition requiring surgical intervention and the surgical procedure itself. A surgically induced tibia fracture or 24 h prior to experimental stroke by permanent middle cerebral artery occlusion (pMCAO) in mice increased lesion volumes and impaired functional outcome. Injury was most severe when pMCAO was induced 6 h after bone fracture. There were
increased numbers of microglia and bone marrow-derived macrophages around the ischemic lesion in mice with tibia fracture, indicating increased inflammation. Moreover, there was a pronounced blood–brain barrier (BBB) breakdown. Detrimental effects were also seen when bone fracture was induced after pMCAO. Poststroke bone fractures are further associated with larger brain edema volumes in subacute stroke stages, potentially due to mentioned BBB breakdown. The detrimental effects of bone fracture on stroke outcome are partially reversed by α7 nicotinic acetylcholine receptor agonists diminishing neuroinflammation and promoting proregenerative mechanisms. These preclinical results strongly indicate that aggravated (neuro-)inflammatory reactions, promoted by pre- or post-stroke bone fracture and surgery, strongly contribute to unfavorable PS outcome. However, the exact mechanisms have not been fully clarified. Importantly, comorbidities frequently seen in elderly or surgically stressed patients such as hypertension can further aggravate innate immune and inflammatory reactions, suggesting a potential relevance in PS.

3 | CHALLENGES AND OPPORTUNITIES FOR EXPERIMENTAL TREATMENT STRATEGIES IN PS

Once proven safe and effective, experimental treatment strategies for stroke may help to counter PS. The idea is supported by the fact that many experimental stroke treatment strategies target neuroinflammation which seems to play a prominent pathophysiological role in PS. In general, experimental treatments should be compatible to recanalization procedures, but may also be applied in PS patients being ineligible for recanalization. However, feasibility, safety, and potential efficacy of experimental treatments must be reviewed considering the particular clinical circumstances in which they would be applied for PS. In this context, it is important to consider that about half of all PS occur within 24 h and 93% within 72 h after surgery. Table 1 provides an overview on potential experimental treatment that may be feasible for PS.

3.1 | Pharmacological neuroprotection

Recent advances in recanalization therapies, especially by mechanical thrombectomy, provide novel opportunities for the restoration of the cerebral blood supply and thus for additional pharmacological neuroprotection. Combining pharmacological neuroprotection with recanalization enables delivery of neuroprotectants exactly where and when needed. Next-generation neuroprotectants such as nerinetide, a postsynaptic density protein 95 inhibitor countering oxidative stress, are clinically tested in combination with recanalization therapies. The advantage of spatially and temporally targeted neuroprotectant delivery only comes to effect for those patients who can benefit from recanalization. However, recanalizing

### TABLE 1

Overview on potential experimental therapeutics for perioperative stroke

| Approach | Advantages | Disadvantages | Safety | Applicability |
|----------|------------|---------------|--------|--------------|
| Pharmacological neuroprotection | Already clinical data in ischemic stroke, could be applied | Most approaches only address one mechanism, efficacy still under | ++ | ++ |
| Inhalative substances | Easy applicability and good control, good effect described for iNO and argon | Some safety concerns with inhalation anesthetics and long-term iNO application, relatively high costs | /- to ++/ | /- to ++/ |
| Intravenous anesthetics | Easy applicability, excellent safety profile | Overall effects unknown and moderate at best | /- to ++/ | /- to ++/ |
| Cell therapies, stem cells | Potentially address multiple mechanisms | Overall safety and concerns for some applications, limited application scenarios | /- to ++/ | /- to ++/ |
| Cell therapies, immune cells | Potentially address multiple mechanisms, good applicability | Overall safety and effects still unclear, still experimental (no clinical data) autologous approaches require ex vivo cell processing | /- to ++/ | /- to ++/ |
| Pre- and postconditioning | Easy applicability, multiple mechanisms, potentially wide therapeutic time window, inexpensive | Still experimental, overall safety and efficacy unclear | /- to ++/ | /- to ++/ |
| Restorative approaches | Long, potentially unlimited therapeutic time window, inexpensive | Still experimental, overall safety and efficacy unclear | /- to ++/ | /- to ++/ |

Abbreviations: ++, very good; +, good; /- to ++, moderate; - , not optimal; ?, unclear; iNO, inhalative nitric oxide.
strategies such as mechanical thrombectomy are still available to the minority of patients with spontaneously occurring stroke, primarily due to a lack of salvageable brain tissue, contraindications, or lack of access to centers performing these techniques. PS patients may experience additional therapeutic restrictions due to late diagnosis (covert PS), their general condition, or specific medications impeding the use of intravenous thrombolysis and partly mechanical thrombectomy. However, these patients would still be eligible for pharmacological neuroprotection as a stand-alone treatment.

For instance, targeting neuroinflammation pathways is a potential neuroprotective strategy for treating ischemic stroke. Salmeron et al. unexpectedly found that the pro-inflammatory cytokine interleukin (IL)-1α exerts therapeutic effects after stroke by promoting proangiogenic and neurogenic mechanisms, potentially outweighing its pro-inflammatory effects. Moreover, Franke et al. demonstrated that the blockade of inflammasome NLR Family Pyrin Domain Containing 3 (NLRP3) molecular protein complexes, which initiate inflammatory responses, limits inflammatory-driven infarct growth during transient (t)MCAO and after recanalization in mice. On the contrary, there is a long history of neutral and negative efficacy trials of stand-alone neuroprotection in the clinic. In addition to quality limitations in some preclinical studies, the previous failure of pharmacological neuroprotection emerged from design differences in preclinical versus clinical trials. For instance, many pharmacological neuroprotectants are most effective when given shortly after stroke onset. This also accounts for nerinetide, which was most effective when given 1.5 h after stroke onset in primates. These narrow time windows are on the lower end of what is achievable in a clinical scenario and seem unrealistic in the context of covert stroke. Analyses from the Highly Effective Reperfusion Using Multiple Endovascular Devices (HERMES) group revealed that time to treatment onset with alteplase was 74–140 min under ideal conditions. Some neuroprotectants even show best efficacy when given prior to stroke onset, what is not realistic in a scenario of spontaneously occurring stroke, but might represent a reasonable strategy for surgical interventions with high risk for PS.

Most surgeries are elective, and clinical investigation may help to identify vulnerable patients prior to PS based on their risk factor profile or the type of surgery they will undergo. Basically, risk factors like heart failure and significant carotid stenoses that may significantly affect brain perfusion during surgery are of special interest in this context. Further, pharmacological neuroprotection can be initiated pre-surgically and maintained throughout all critical surgical and postsurgical periods. Combination of different neuroprotectants might be applied to cover multiple stroke pathomechanisms. This approach may not prevent PS per se, but potentially alleviate ischemic damage.

A single study reported the application of edaravone, a free radical scavenger which is used in Japan since 2001, in hypoxic–ischemic brain injury caused by unilateral common carotid artery occlusion plus hypoxia (7.5% O₂/92.5% N₂ applied via face mask) in mice. Prophylactic, that is, 30 min prior to the hypoxic–ischemic injury, but not delayed edaravone application mitigated ischemic tissue damage and improved functional outcome. Despite these encouraging findings, we still lack profound proof of concept for the perioperative neuroprotection paradigm, and future preclinical research is needed to explore potential therapeutic opportunities.

Another interesting option is metabolic support of brain tissue at risk for infarction. This paradigm would neither prevent PS nor long-term tissue damage. However, it may decelerate penumbra decline and thus increase the time available for recanalization interventions. Options comprise the pharmacological increase of collateral perfusion or replenishment of energy-containing substrates such as adenosine triphosphate. Although additional preclinical investigations are required to further assess and optimize the metabolic support paradigm particularly in an experimental PS setting, it was already applied successfully in aged animals and subjects expressing comorbidities similar to those of patients at risk for PS. Although successful, therapeutic effects are moderate and best only if the metabolic support is started relatively early after stroke onset. The approach could be initiated prior to surgical interventions in patients characterized by a relevant risk for PS. It might particularly benefit those in whom PS is not caused by a major embolic event blocking blood flow to a certain brain area, but primarily on cerebral hyperfusion during surgery with a residual blood flow to the affected area. Notably, specific agents may also extend the time window for vascular recanalization and further neuroprotectant administration.

In summary, pharmacological neuroprotection represents a promising strategy in the setting of PS based on the unique fact that initiating neuroprotection is possible prior to the ischemic event.

### 3.2 Inhalative substances

Some frequently used volatile anesthetics and other gaseous compounds are reported to have neuroprotective capabilities, which might be particularly valuable in a perioperative setting. Isoflurane and sevoflurane exposure prior to, during, and after cerebral ischemia was shown to reduce brain damage in rodents. The therapeutic effects include a reduction in lesion volume, improvement of functional outcome, attenuation of reactive astrogliosis, and promotion of anti-inflammatory microglial and macrophage phenotypes. Research revealed numerous molecular pathways that mediate the beneficial effects of volatile anesthetics.

There is strong evidence for isoflurane-induced neuroprotection. Ischemic damage is inversely related to duration and dose of isoflurane anesthesia in tMCAO. Neuroprotective effects persisted at least 8 weeks after focal cerebral ischemia in rats. These effects are so strong that they may even mask the therapeutic
benefits of potential neuroprotective drugs in stroke models. Moreover, volatile anesthetics including isoflurane show a dose-dependent protective effect on the incidence and severity of early postoperative ischemic stroke in patients undergoing non-cardiac surgery.

On the contrary, both isoflurane and sevoflurane also exert detrimental effects on cognitive function in fetal and aged brains both in experimental models and patients although their impact is still controversially discussed for healthy adults. Both agents are also believed to induce inflammation-mediated neurotoxicity in the young adult and aged brain. Isoflurane also opens the blood–brain barrier. Moreover, anesthesia is often related to hypotension what is critical in the context of ischemic stroke.

Interestingly, neurotoxic effects predominantly emerge in the absence of brain injury, while neuroprotective effects are observed in cases of ischemic or traumatic brain injury. A potential reason is the reduction in neuronal activity and metabolism during anesthesia, which indeed would be beneficial in stroke but not in the steady state. Although this does not prevent the use of volatile anesthetics in patients at risk for PS, it does not suggest them as first-line stand-alone therapeutics. When considering a therapeutic application, sevoflurane might have the advantage of better applicability and a favorable safety profile in clinical settings. However, its application deserves detailed experimental investigation in perioperative setups including a thorough assessment of protective and potential toxic effects to define its value for mitigating PS damage.

Normobaric and hyperbaric oxygenation have been discussed as potential neuroprotective approaches for decades. Currently, normobaric oxygenation is revisited. Meta-analysis indicates a potential benefit of the approach, but large-scale multicenter clinical trials are needed to assess this potential benefit. The situation is comparable for hyperbaric oxygenation. Results of these ongoing assessments in spontaneous stroke should be awaited before discussing a potential application in PS.

Profound neuroprotective effects were also shown for other substances such as inhalational nitric oxide (iNO). iNO dilates blood vessels in areas of low oxygen concentrations. This effect is clinically utilized since the 1990s, for instance in newborns with persistent hypertension due to pulmonary vasoconstriction. iNO also increases cerebral blood flow in the penumbra during acute stroke. However, long-term application of iNO comes with drawbacks such as methemoglobin formation and may cause mild to moderate hypotension. Enhanced NO levels in the neuronal compartment are toxic, but the relatively short half-life of NO and its rapid binding to hemoglobin make iNO an unlikely cause of neurotoxicity, especially when applied at concentrations of 50 ppm or lower. These low concentrations also alleviate the risk of a relevant reduction in blood pressure and thus cerebral perfusion, what would be particularly dangerous in an intensive care or surgical setting, characterized by periods of hypotension and vasopressor support. The challenges related to long-term iNO application currently exclude it as an option for PS prevention, but it could play a role in prolonging the therapeutic time window for recanalization therapies should PS be detected.

The application of hydrogen has been reported in experimental stroke. The primary mode of action seems to be antioxidation that counters cytotoxic effects of reactive oxygen species. Hydrogen also possesses strong anti-inflammatory effects that can be beneficial after stroke. For instance, hydrogen can attenuate post-stroke activation of microglia while shifting microglial polarization toward the anti-inflammatory M2 type. Hydrogen also attenuates the increase of pro-inflammatory M1 macrophages. Anti-apoptotic effects of hydrogen have been reported, and it stabilizes the blood–brain barrier after stroke in hypertensive rats. Of note, hydrogen can also be applied intravenously after being enriched in saline. The procedure is safe in patients after ischemic stroke including those treated with tissue plasminogen activator. Hydrogen application seems to be safe even in higher concentrations although the expression of certain enzymes such as aspartate aminotransferase, alanine aminotransferase, and γ-glutathione transferase can decline after exposure. Application of hydrogen to mitigate PS may be considered after defining the most effective way of administration (gaseous versus enriched in saline) and further confirming safety. An advantage may be its compatibility with recanalization approaches and effectiveness in comorbid individuals.

Noble gases such as xenon and argon can exert neuroprotective effects. Argon may be preferred over xenon as it is less sedative and shows robust beneficial effects in experimental stroke and global cerebral ischemia. Argon reduces ischemic lesion size and improves functional outcome after 2 h of tMCAO and prolonged exposure of 24 h is safe in rodents. Argon application is also safe in hemorrhagic stroke. Preclinical data are missing on PS, and argon was not yet applied clinically for NS stroke or PS. However, it might be an interesting therapeutic candidate for both PS prevention and treatment even in patients being ineligible for recanalization therapies because it is even beneficial after pMCAO. When applied therapeutically, the need for timely PS diagnosis remains.

### 3.3 Intravenous anesthetics for neuroprotection

Propofol was found to exert neuroprotective effects after ischemic stroke in preclinical studies. In detail, Adembri et al. demonstrated that propofol reduced infarct size and preserved spontaneous activity in rats and that propofol at a clinically relevant concentration mediated these protective effects by attenuating swelling of neuronal mitochondria. More recently, Wang et al. infused propofol at reperfusion after tMCAO and found decreased infarct size and attenuated neurological deficits in the propofol treated group, in which neurotoxic aggregation of α-synuclein was also reduced. However, these findings raised discussions as a randomized clinical trial with 66 patients undergoing intracranial aneurysm surgery could not reveal protective propofol effects on postoperative cognitive function.

Ketamine and dexmedetomidine are other, frequently applied anesthetic drugs with potential neuroprotective effects. Ketamine has anti-apoptotic and anti-neuroinflammatory effects after brain damage and preserves cognitive function after major cardiac
surgery in humans.\textsuperscript{85–87} Most recently, Xiong et al. showed that MCAO-induced brain damage was significantly attenuated by administration of (R)-ketamine, but not (S)-ketamine. The effect was seen after treatment prior to or after MCAO.\textsuperscript{88} Dexmedetomidine is a selective \( \alpha_2 \)-adrenergic agonist that was tested as a neuroprotective agent in experimental stroke models. Dexmedetomidine at a dose of 3 \( \mu \)g/kg given subcutaneously 30 min before and 3, 12, 24, and 48 h after global ischemia in gerbils protected neurons in the hippocampal CA3 and dentate gyrus.\textsuperscript{89} Intravenous infusion of dexmedetomidine (9 \( \mu \)g/kg) during tMCAO decreased infarct volume by 40\%, being more effective than the NMDA receptor antagonist CGS-19755, although a minor increase in blood glucose and hypotension was observed.\textsuperscript{90} Despite these early yet promising results, dexmedetomidine was never tested in clinical neuroprotection trials. However, due to its broad sedative, anxiolytic, analgesic, sympatholytic, and stable hemodynamic profile, dexmedetomidine is now used as an adjuvant for premedication, especially in patients susceptible to preoperative and perioperative stress. More importantly, dexmedetomidine improves cognition after carotid endarterectomy,\textsuperscript{91} reduces postoperative delirium after joint replacement surgery,\textsuperscript{92} and attenuates postoperative disability after cranial surgery,\textsuperscript{93} pointing at its potential neuroprotective properties in a peripro- active setting. Dexmedetomidine also reduces inflammatory factor expression and enhanced brain-derived neurotrophic factor (BDNF) levels.\textsuperscript{94} Moreover, dexmedetomidine may mediate neuroprotective effects by anti-apoptosis and suppression of immune responses.\textsuperscript{94–96} Whether or not injection anesthetics might be beneficial in PS remains to be investigated preclinically before moving on to any clinical assessment. Potential detrimental effects of anesthesia-induced hypotension as discussed for volatile anesthetics must also be considered.

### 3.4 Cell therapies

Immune and stem cell therapies (ICT and SCT, respectively) were extensively investigated in animal models of ischemic stroke and are considered a promising therapeutic option.\textsuperscript{97,98} In the field of ICTs, regulatory T-cell therapy is an important approach. CD4\(^{+}\)CD25\(^{+}\)Foxp3\(^{+}\) regulatory T (Treg) cells exert neuroprotection after ischemic stroke by suppressing neuroinflammation.\textsuperscript{99,100} Adoptive transfer of Tregs was shown to ameliorate BBB damage in the acute phase of stroke\textsuperscript{101} and accelerates neural stem cell propagation in the subsequent brain repair phase.\textsuperscript{102} Inhibitory signaling molecules such as cytotoxic T-lymphocyte-associated protein 4, programmed cell death-ligand 1, and IL-10 contribute to the Treg-mediated attenuation of neuroinflammation after stroke.\textsuperscript{103–105} Tregs also promote neural stem cell proliferation by secreting IL-10 and by suppressing astrogliosis.\textsuperscript{106,107} Treg-derived osteopontin promoted post-stroke white matter repair and functional recovery by fostering regenerative capacities of microglia via integrin receptor-mediated signaling.\textsuperscript{104} Consistently, Ito et al. found that Tregs suppress astrogliosis and foster neurological recovery, and that these processes peak about 2 weeks after stroke.\textsuperscript{108} However, the therapeutic window for Treg transplantation is not known. Age\textsuperscript{109} and sex\textsuperscript{110,111} can influence the potency of Tregs and also affect microglial function.\textsuperscript{112} Any beneficial effects of ICTs in NS stroke or PS remain to be clinically investigated.

Another option of cell therapy for NS stroke is SCT. First clinical trials are underway to assess SCT safety and efficacy in NS stroke.\textsuperscript{113–116} Adult cell populations such as mesenchymal stem cells (MSCs) from bone marrow\textsuperscript{117,118} or adipose tissue, as well as mononuclear cell populations from bone marrow or umbilical cord blood (containing a stem cell fraction), are predominantly applied due to their proper safety profile, good applicability in a clinical setting, and the option for autologous treatment preventing potential immunological consequences.\textsuperscript{119} Nevertheless, allogeneic cell products including neural and neuronal stem and progenitor cells are also investigated. Allogeneic populations provide the advantage of being readily available as an off-the-shelf product and can be modified a priori to increase therapeutic efficacy.

Adult SCTs exert their therapeutic effects by indirect, mainly paracrine (“bystander”) functions.\textsuperscript{120} Particularly, they promote angiogenesis,\textsuperscript{121,122} modify and mitigate reactive astrogliosis, exert general neuroprotective effects,\textsuperscript{123} or increase endogenous progenitor cell proliferation in the brain.\textsuperscript{124} Some populations such as MSCs also exhibit strong immunomodulatory and -suppressive abilities,\textsuperscript{125–127} what might be useful given that aggravated neuroinflammation is an important PS pathomechanism.

However, SCTs may not be a first-line treatment for PS, and application could be restricted to selected patient populations.\textsuperscript{24} A recent meta-analysis showed that the clinical efficacy of adult SCTs in NS stroke currently stays behind therapeutic effects reported in preclinical studies. For instance, the bystander therapeutic effects of adult SCTs predominantly target pathomechanisms in acute and subacute stroke stages, meaning that their effective application has a therapeutic time window.\textsuperscript{128,129} Although quality of preclinical stroke research, a known limiting factor for clinical translation in the past, has clearly improved,\textsuperscript{130} design differences between preclinical and clinical trials may contribute to minor efficacy seen in clinical trials.\textsuperscript{131} On the contrary, requirements of best practice stroke treatments often interfere with the application of SCTs, requiring an extension of the therapeutic time window of SCTs in clinical trials for logistical reasons. This, however, may significantly decrease SCT efficacy.\textsuperscript{115} Moreover, obtaining cells from autologous sources such as bone marrow or adipose tissue requires additional invasive procedures. This can be challenging, for instance in trauma patients undergoing surgery. Thus, SCTs for PS might be restricted to commercially available allogeneic cell products unless a previous “preventive” preservation of autologous cells was performed for the patient.

Finally, the application of adult cell populations, regardless of being autologous or allogeneic, is not free of risks. Improper intravenous or intra-arterial administration of larger cells such as MSCs may cause pulmonary\textsuperscript{132} or cerebral embolism,\textsuperscript{133} respectively. Long-term cryopreservation may further affect viability
and subpopulation composition of adult cell populations. This may even reduce therapeutic efficacy in some populations. Extracellular vesicles (ECVs) might be a potential alternative. ECVs are released from cells upon fusion of the multivesicular body (an intermediate endocytotic compartment) with the plasma membrane. ECVs are involved in inter-cellular communication over long distances and contain messenger molecules and cytokines believed to mediate the therapeutic bystander effects reported for adult cell populations in stroke. Thus, ECVs derived from adult stem cell populations exert therapeutic effects similar to those of the cells. Moreover, they are much smaller and less immunogenic than allogeneic cells, avoiding many of the challenges associated with the use of adult cell populations. ECV application is also compatible with other conventional or experimental PS treatments as it only requires systemic bolus injection or infusion. However, there is no detailed knowledge on their efficacy in PS, and methods for ECV production have not yet reached an industrial scale and quality. Appropriate potency assays are also lacking.

3.5 | Pre- and postconditioning strategies

Conditioning strategies are an emerging paradigm in experimental stroke research and already showed remarkable effects in other ischemic conditions such as myocardial infarction. Conditioning could be applied before (ischemic preconditioning; iPreC) or after the ischemic event (ischemic postconditioning; iPoC). The principle of iPreC is to expose the target organ (or a peripheral target) to one or multiple brief ischemic episodes. This induces tolerance against subsequent and more severe ischemic injuries, including in the brain. The effect is mediated by profound changes in cellular gene expression, for instance downregulating metabolism and immune responses. Similar to neuroprotection prior to the ischemic injury, iPreC may not play a major role in NS stroke, but would be applicable in patients at high risk for PS. Although the brain itself can be conditioned effectively in experimental subjects, the clinically preferred approach would be remote iPreC, for instance in a limb (peripheral conditioning).

The therapeutic mechanisms of iPoC differ from those of iPreC. They include the mitigation of reperfusion injury and post-stroke edema, BBB protection, and reduction in apoptosis. Some studies suggest that the therapeutic time window for remote iPoC may be surprisingly wide. Although a reduction in infarct volume was achieved only when applying iPoC within 24 h after 60 min tMCAO in mice, best functional recovery and even limited neuroregeneration was seen when iPoC started 5 days after tMCAO. Moreover, iPoC may extend the therapeutic time window for recanalization. Importantly, conditioning approaches are already tested clinically, and there is preliminary evidence for a modest therapeutic benefit in non-human primates and humans. However, as in other fields, there are design differences between preclinical and clinical studies so final appraisal of the therapeutic impact is not yet possible.

There are also non-ischemic conditioning strategies. For instance, a single pretreatment with isoflurane induces ischemic tolerance in the rat brain. Multiple mechanisms are likely to be involved including reduced apoptosis via activation of the mitogen-activated protein kinase (MAP) kinase ERK (p42/44) and protein kinase B (Akt). However, whether neuroprotection is persistent and effective in high-risk patients remains open. Conditioning strategies appear as an easily applicable and safe option for PS prevention and therapy. Both iPreC and iPoC protocols could be applied in surgical patients, with some restrictions in trauma patients. Research is underway to unravel the exact mechanisms and mediators behind conditioning effects. Thus, the approach may turn into a pharmacological one in future, removing further hurdles for widespread application. Another advantage is that conditioning strategies can be applied reproducibly and at very low costs, not interfering much with standard care procedures even in an intensive care setting. However, neither preclinical nor clinical assessments of conditioning strategies were performed in PS so far. Moreover, preclinical research is warranted to optimize application, duration, and timing of conditioning strategies in PS before moving forward to early-stage clinical trials.

3.6 | Restorative approaches

Tissue restoration after stroke, regardless of occurring spontaneously or as PS, is currently thought to be challenging. The reason is a lack of anatomical, cellular, and molecular cues allowing the recapitulation of brain development as seen during ontogenesis. Biomaterials and scaffolds may help to provide such cues in larger lesions, whereas smaller lesions or those predominantly situated in the white matter may be attractive targets for restorative therapies. However, a profound preclinical proof of concept of restorative approaches is not available so far, and any clinical application is unlikely to happen in the near future.

Another aspect of a potential brain repair is attracting increasing attention recently. Immune cell-mediated long-term neuroinflammation is an intriguing target for strategies trying to address or modulate various endogenous regenerative processes such as neurogenesis, white matter repair, and others.

4 | EXPERIMENTAL DIAGNOSTIC APPROACHES FOR CRITICALLY ILL POSTSURGICAL PATIENTS

A major challenge in PS management is its timely detection intra-surgically or in the immediate postsurgical phase, and the clinical assessment is generally limited by the existing unconscious condition or reduced consciousness of the patient. Furthermore, postsurgical care, in particular for trauma patients, may require intensive anesthesia or even sedation in an intensive care setting, further complicating timely PS diagnosis. Brain imaging technologies such as...
magnetic resonance imaging and computed tomography are limited diagnostic options for the screening of PS, since they would need to be applied frequently.

An alternative method being under consideration for decades is electroencephalography (EEG) which has a high sensitivity in detecting pathological events in the brain. Difficulties in discriminating old versus new strokes, detecting strokes in sedated patients, and relatively low spatial resolution limit the use of EEG in PS. New data provide evidence that EEG might be a possible tool for the detection of stroke due to large artery occlusion, but this approach requires verification in further studies. Near-infrared spectroscopy (NIRS) might be very sensitive in detecting cortical strokes. However, false-negative results are possible due to a limited field of detection or in strokes located below the cortex.

Other technologies based on ultrasound and volumetric impedance phase-shift spectroscopy are under development, but available data are not yet comprehensive enough for thorough validation of diagnostic feasibility in PS. An optimal diagnostic approach should also provide information on the location of the vessel occlusion which is essential for the individual consideration of recanalizing attempts.

Potential stroke biomarkers including purines, pentoxypoline, D-dimers in combination with glial fibrillary acidic protein, or glutamate plus interleukin were investigated as potential stroke biomarkers. All can be detected from blood samples. This allows continuous surveillance of patients at risk for PS. Although some approaches have a decent specificity and others such as broad metabolomic screening may discriminate stroke subtypes, a general problem of many biomarkers is a relatively low specificity. However, low specificity of biomarker-based or other point-of-care stroke diagnostics is not necessarily a problem since reliable PS diagnosis may rely on a two-step strategy. Highly sensitive and continuously applicable screening methods aiming to recognize any suspicious alteration as early as possible, and not interfering with gold standard care, would be applied in the first instance. In case of any abnormality being detected, conventional brain imaging to exclude PS or to decide about immediate therapeutic interventions is performed immediately. This two-step strategy, in theory, may facilitate timely treatment of PS in critically ill patients. In practice, there would be limitations regarding the availability of the screening methods and trained staff to apply them reliably, as well as by costs incurring for continuous screening. Further clinical studies aiming to define the most feasible setup and confirming true therapeutic benefits will be required. Table 2 provides examples for potential stroke biomarkers which have shown promising results in clinical applications.

### Table 2: Examples for potential stroke biomarkers

| Marker | Study type | Patient details | Advantages | Disadvantages | Reference |
|--------|------------|----------------|------------|---------------|-----------|
| Purines | Single-center, prospective observational | 18 patients undergoing carotid endarterectomy | Very sensitive, no complex sample processing, immediate results | Low specificity | 161 |
| D-dimers + GFAP | Single-center, prospective observational | 239 patients with suspected strokes in two derivation cohorts (n = 128) and validation cohort (n = 111) | High sensitivity and specificity, allows to safely triage large vessel occlusion patients (AUC = 93%) | Based on standard ELISA in its present form, thus time consuming and not yet eligible for screening | 163 |
| Glutamate + IL-6 | Single-center, retrospective | 4775 stroke patients | High sensitivity and good specificity, indicate patients for recanalization | No data on hemorrhagic strokes yet, not sure whether diagnostic signature overlaps with other conditions | 164 |
| Asymmetric and symmetrical dimethylarginine, pregnenolone sulfate, and adenosine | Single-center, prospective observational | Patients with strokes (n = 508) and stroke mimics (n = 349), neurologically normal controls (n = 112) | High accuracy in discriminating ischemic stroke from stroke mimics | No data on hemorrhagic strokes yet, not sure whether diagnostic signature overlaps with other conditions | 165 |

**Abbreviations:** AUC, area under the curve; ELISA, enzyme-linked immunosorbent assay; GFAP, glial fibrillary acidic protein; IL, interleukin.

### 5 SUMMARY AND CONCLUSIONS

Perioperative stroke currently remains a feared condition due to a relatively high incidence and poor functional outcome. Established stroke treatments aiming at recanalization are of limited use in PS patients for several reasons including their narrow time windows...
and contraindications emerging from an increased bleeding risk. Experimental treatment strategies including peri-surgical pharmacological neuroprotection, inhalative substances, as well as pre- and postconditioning approaches may improve PS prevention and treatment. However, we still lack profound translational and clinical data on safety and efficacy of these approaches, as well as continuously applicable diagnostic option for timely PS detection during surgery or in sedated patients. Collaborations between preclinical scientists, surgeons, neurologists, and anesthesiologists are required to improve PS management and outcome. Patients being at risk for PS would also benefit from internationally harmonized, evidence-based consensus guidelines for PS diagnosis, management, and care.

ACKNOWLEDGEMENTS

P.L. and J.B. conceptualized the topic. X.J., P.L., and J.B. and drafted the first version of the manuscript. All authors provided content based on their respective expertise, reviewed, and agreed to the final manuscript version. P.L. is supported by the National Natural Science Foundation of China (NSFC, 91957111, 82061130224), and P.L. and J.B. were supported by the Newton Advanced Fellowship grant provided by the UK Academy of Medical Sciences (NAF\ R11\1010). This work is also supported by the Shanghai Engineering Research Center of Peri-operative Organ Support and Function Preservation (20DZ2254200).

CONFLICT OF INTEREST

The authors declare that there are no competing interests.

ORCID

Shen Li https://orcid.org/0000-0001-6779-9812
Lili Cui https://orcid.org/0000-0002-6931-7263
Johannes Boltze https://orcid.org/0000-0003-3956-4164

REFERENCES

1. Mashour GA, Moore LE, Lele AV, Robicsek SA, Gelb AW. Perioperative care of patients at high risk for stroke during or after non-cardiac, non-neurologic surgery: consensus statement from the society for neuroscience in anesthesiology and critical care’. J Neurosurg Anesthesiol. 2014;26(4):273-285.
2. Bateman BT, Schumacher HC, Wang S, Shaefi S, Berman MF. Perioperative acute ischemic stroke in noncardiac and nonvascular surgery: incidence, risk factors, and outcomes. Anesthesiology. 2009;110(2):231-238.
3. Ko SB. Perioperative stroke: pathophysiology and management. Korean J Anesthesiol. 2018;71(1):3-11.
4. Mazzeffi M, Chow JH, Anders M, et al. Intraoperative hypotension and perioperative acute ischemic stroke in patients having major elective non-cardiovascular non-neurological surgery. J Anesth. 2021;35(2):246-253.
5. Selim M. Perioperative stroke. N Engl J Med. 2007;356(7):706-713.
6. Ng JL, Chan MT, Gelb AW. Perioperative stroke in noncardiac, nonneurosurgical surgery. Anesthesiology. 2011;115(4):879-890.
7. Mashour GA, Shanks AM, Khetarpal S. Perioperative stroke and associated mortality after noncardiac, nonneurologic surgery. Anesthesiology. 2011;114(6):1289-1296.
8. Smilowitz NR, Gupta N, Ramakrishna H, Guo Y, Berger JS, Bangalore S. Perioperative major adverse cardiovascular and cerebrovascular events associated with noncardiac surgery. JAMA Cardiol. 2017;2(2):181-187.
9. Buceriues J, Gumertt JF, Borger MA, et al. Stroke after cardiac surgery: a risk factor analysis of 16,184 consecutive adult patients. Ann Thorac Surg. 2003;75(2):472-476.
10. Neuro VI. Perioperative covert stroke in patients undergoing non-cardiac surgery (NeuroVISION): a prospective cohort study. Lancet. 2019;394(10203):1022-1029.
11. Benesch C, Glance LG, Derdeyn CP, et al. Perioperative neurologic evaluation and management to lower the risk of acute stroke in patients undergoing noncardiac, nonneurological surgery: a scientific statement from the American heart association/American stroke association. Circulation. 2021;143(19):e923-e246.
12. Wang H, Li SL, Bai J, Wang DX. Perioperative acute ischemic stroke increases mortality after noncardiac, nonvascular, and nonneurologic surgery: a retrospective case series. J Cardiothorac Vasc Anesth. 2019;33(8):2231-2236.
13. Leary MC, Varade P. Perioperative stroke. Curr Neurol Neurosci Rep. 2020;20(5):12.
14. Vilisis PE, Moore LE, Whalin MK, et al. Perioperative care of patients at high risk for stroke during or after non-cardiac, non-neurological surgery: 2020 guidelines from the society for neuroscience in anesthesiology and critical care. J Neurosurg Anesthesiol. 2020;32(3):210-226.
15. Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American heart association/American stroke association. Stroke. 2016;47(2):581-641.
16. Voelkel N, Hubert ND, Backhaus R, Haberl RL, Hubert GJ. Thrombolysis in postoperative stroke. Stroke. 2017;48(11):3034-3039.
17. McCollBW, Allan SM, Rothwell NJ. Systemic infection, inflammation and acute ischemic stroke. Neurosci. 2009;158(3):1049-1061.
18. Naylor AR, Mehta Z, Rothwell PM, Bell PR. Carotid artery disease and stroke during coronary artery bypass: a critical review of the literature. Eur J Vasc Endovasc Surg. 2002;23(4):283-294.
19. Yamaguchi A, Adachi H, Tanaka M, Ino T. Efficacy of intraoperative epiaortic ultrasound scanning for preventing stroke after coronary artery bypass surgery. Ann Thorac Cardiovasc Surg. 2009;15(2):98-104.
20. Matoba T, Sato K, Egashira K. Mouse models of plaque rupture. Curr Opin Lipidol. 2013;24(5):419-425.
21. Janssen H, Wagner CS, Demmer P, et al. Acute perioperative-stress-induced increase of atherosclerotic plaque volume and vulnerability to rupture in apolipoprotein-E-deficient mice is amenable to statin treatment and IL-6 inhibition. Dis Model Mech. 2015;8(9):1071-1080.
22. Wang L, Kang S, Zhou D, et al. Bone fracture pre-ischemic stroke exacerbates ischemic cerebral injury in mice. PLoS One. 2016;11(4):e0153835.
23. Li Z, Wei M, Lyu H, et al. Fracture shortly before stroke in mice leads to hippocampus inflammation and long-lasting memory dysfunction. J Cereb Blood Flow Metab. 2020;40(2):446-455.
24. Yasuhara T, Kawauchi S, Kin K, et al. Cell therapy for central nervous system disorders: current obstacles to progress. CNS Neurosci Ther. 2020;26(6):595-602.
25. Huang J, Lyu H, Hao K, et al. Bone fracture enhanced blood-brain barrier breakdown in the hippocampus and white matter damage of stroke mice. Int J Mol Sci. 2020;21(22):8481.
26. Degos V, Maze M, Vacas S, et al. Bone fracture exacerbates murine ischemic cerebral injury. Anesthesiology. 2013;118(6):1362-1372.
27. Zou D, Luo M, Han Z, et al. Activation of alpha-7 nicotinic acetylcholine receptor reduces brain edema in mice with ischemic stroke and bone fracture. Mol Neurobiol. 2017;54(10):8278-8286.
28. Huo K, Wei M, Zhang M, et al. Reduction of neuroinflammation alleviated mouse post bone fracture and stroke memory dysfunction. *J Cereb Blood Flow Metab*. 2021;41(9):2162-2173.

29. Han Z, Li L, Wang L, Degos V, Maze M, Su H. Alpha-7 nicotinic acetylcholine receptor agonist treatment reduces neuroinflammation, oxidative stress, and brain injury in mice with ischemic stroke and bone fracture. *J Neurochem*. 2014;131(4):498-508.

30. Moller K, Posel C, Kranz A, et al. Arterial hypertension aggravates innate immune responses after experimental stroke. *Front Cell Neurosci*. 2015;9:461.

31. Chen C, Huang T, Zhai X, et al. Targeting neutrophils as a novel therapeutic strategy after stroke. *J Cereb Blood Flow Metab*. 2021;41(9):2150-2161.

32. Campbell BCV, Donnan GA, Lees KR, et al. Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke. *Lancet Neurol*. 2015;14(8):846-854.

33. Lyden P, Buchan A, Bolzle J, Fisher M, Consortium*. SX. Top priorities for cerebroprotective studies- a paradigm shift: report from STAIR XI. *Stroke*. 2021;52(9):3063-3071.

34. Hill MD, Goyal M, Menon BK, et al. Efficacy and safety of neri- netide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. *Lancet*. 2020;395(10227):878-887.

35. McMeein P, White P, James MA, Price CI, Flynn D, Ford GA. Estimating the number of UK stroke patients eligible for endovascular thrombectomy. *Eur Stroke J*. 2017;2(4):319-326.

36. Salmeron KE, Maniskas ME, Edwards DN, et al. Interleukin 1 in animal models of traumatic brain injury in rats. *J Neuroinflammation*. 2019;16(1):222.

37. Franke M, Bieber M, Kraft P, Weber ANR, Stoll G, Schulhammer MK. The NRLP3 inflasmasome drives inflammation in ischemia/ reperfusion injury after transient middle cerebral artery occlusion in mice. *Brain Behav Immun*. 2021;92:223-233.

38. O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. *Brain*. 2006;59(3):467-477.

39. Sommer CJ, Schabitz WR. Principles and requirements for stroke recovery science. *J Cereb Blood Flow Metab*. 2021;41(3):471-485.

40. Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. *Nature*. 2012;483(7388):213-217.

41. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet*. 2016;387(10029):1723-1731.

42. Sun YY, Li Y, Wali B, et al. Prophylactic edaravone prevents transient hypoxic-ischemic brain injury: implications for perioperative neuroprotection. *Stroke*. 2015;46(7):1947-1955.

43. Hou K, Li G, Yu J, Xu K, Wu W. Receptors, channel proteins, and enzymes involved in microglia-mediated neuroinflammation and treatments by targeting microglia in ischemic stroke. *Neuroscience*. 2021;460:167-180.

44. Chan SL, Bishop N, Li Z, Cipolla MJ. Inhibition of PAI (plasminogen activator inhibitor)-1 improves brain collateral perfusion and injury after acute ischaemic stroke in aged hypertensive rats. *Stroke*. 2018;49(8):1969-1976.

45. Cipolla MJ, Linfante I, Abuchowski A, Jubin R, Chan SL. Pharmacologically increasing collateral perfusion during acute stroke using a carboxyhemoglobin gas transfer agent (Sanguinate) in spontaneously hypertensive rats. *J Cereb Blood Flow Metab*. 2018;38(5):755-766.

46. Fuller KME, Leach J, Johnston P, Holmes WM, Macrae IM, Frengueli BG. Proof of concept and feasibility studies examining the influence of combination ribose, adenosine and allopurinol treatment on stroke outcome in the rat. *Brain Neurosci Adv*. 2017;1:2398212817717112.
77. Takeuchi S, Nagatani K, Otani N, et al. Hydrogen improves neuronal function in a mouse model of ischemic stroke. Acta Neurol Scand. 2009;53(7):864-872.
78. Bell JD. In vogue: ketamine for neuroprotection in acute neurological injury. Anesth Analg. 2017;124(4):1237-1243.
79. Shu L, Li T, Han S, et al. Inhibition of neuron-specific CREB dephosphorylation is involved in propofol and ketamine-induced neuroprotection against cerebral ischemic injuries of mice. Neurochem Res. 2012;37(1):49-58.
80. Xiong Z, Chang L, Qu Y, et al. Neuronal brain injury after cerebral ischemic stroke is ameliorated after subsequent administration of (R)-ketamine, but not (S)-ketamine. Pharmacol Biochem Behav. 2020;191:172904.
81. Kuhmonen J, Pokorny J, Miettinen R, et al. Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Anesthesiology. 1997;87(2):371-377.
82. Jolkkonen J, Puurunen K, Koistinaho J, et al. Neuroprotection by the alpha2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia. Eur J Pharmacol. 1999;372(1):31-36.
83. Ge Y, Li Q, Nie Y, et al. Dexmedetomidine improves cognition after carotid endarterectomy by inhibiting cerebral inflammation and enhancing brain-derived neurotrophic factor expression. J Int Med Res. 2019;47(6):2471-2482.
84. Liu Y, Ma L, Gao M, Guo W, Ma Y. Dexmedetomidine reduces postoperative delirium after joint replacement in elderly patients with mild cognitive impairment. Aging Clin Exp Res. 2016;28(4):729-736.
85. Chen PH, Tsuang FY, Lee CT, et al. Neuroprotective effects of intraoperative dexmedetomidine infusion combined with goal-directed haemodynamic therapy for patients undergoing cranial surgery A randomised controlled trial. Eur J Anaesthesiol. 2021.
86. Zhang F, Ding T, Yu L, Zhong Y, Dai H, Yan M. Dexmedetomidine protects against oxygen-glucose deprivation-induced injury through the I2 imidazoline receptor-I2K/ATP pathway in rat C6 glioma cells. J Pharm Pharmacol. 2012;64(1):120-127.
87. Wang L, Liu H, Zhang L, Wang G, Zhang M, Yu Y. Neuroprotection of dexmedetomidine against cerebral ischemia-reperfusion injury in rats: involved in inhibition of NF-kappaB and inflammation response. Biomed Res Int. 2014;2014:2014.
88. Savitz SI, Chopp M, Deans R, et al. Stem cell therapies as an emerging paradigm in Stroke P. Stem cell therapies as an emerging paradigm in stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke. 2009;40(2):510-515.
89. Mracsko E, Liesz A, Stojanovic A, et al. Antigen dependent activation of CD4+ T cells in ischemic stroke. J Neurosci Res. 2014;34(50):16784-16795.
90. Wang H, Wang Z, Wu Q, Yuan Y, Cao W, Zhang X. Regulatory T cells in ischemic stroke. CNS Neurosci Ther. 2021;27(6):643-651.
91. Li P, Wang L, Zhou Y, et al. C-C chemokine receptor type 5 (CCR5)-mediated docking of transferred tregs protects against early blood-brain barrier disruption after stroke. J Am Heart Assoc. 2017;6(8):e006387.
92. Wan YY. Multi-tasking of helper T cells. Immunology. 2010;130(2):166-171.
93. Rodriguez-Perea AL, Gutierrez-Vargas J, Cardona-Gomez GP, Guarin CJ, Rojas M, Hernandez PA. Atorvastatin modulates regulatory T cells and attenuates cerebral damage in a model of transient middle cerebral artery occlusion in rats. J Neuroimmunol Pharmacol. 2017;12(1):152-162.
104. Liesz A, Suri-Payer E, Veltkamp C, et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. *Nat Med*. 2009;15(2):192-199.

105. Haq R, Aras R, Besachie DA, Borgie RC, Audette MA. 3D lumbar spine intervertebral disc segmentation and compression simulation from MRI using shape-aware models. *Int J Comput Assist Radioi Surg*. 2015;10(1):45-54.

106. Wang J, Xie L, Yang C, et al. Activated regulatory T cell regulates neural stem cell proliferation in the subventricular zone of normal and ischemic mouse brain through interleukin 10. *Front Cell Neurosci*. 2015;9:361.

107. Nyenhuis SM, Schwantes EA, Mathur SK. Characterization of leukotrienes in a pilot study of older asthma subjects. *Immun Ageing*. 2010;7:8.

108. Ito M, Komai K, Mise-Omata S, et al. Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery. *Nature*. 2019;565(7738):246-250.

109. Guo Z, Wang G, Wu B, et al. DCAF1 regulates treg senescence. *CNS Neurosci Ther*. 2020;26(3):288-296.

110. Vasanthakumar A, Chisanga D, Blume J, et al. Sex-specific endothelial progenitor cells: implications for vascular disease and aging. *Circulation*. 2015;131(18):1750-1758.

111. Xin H, Liu Z, Buller B, et al. DCAF1 regulates treg senescence. *CNS Neurosci Ther*. 2020;26(3):288-296.

112. Bolte J, Reich DM, Hau S, et al. Assessment of neuroprotective effects of human umbilical cord blood mononuclear cell subpopulations in vitro and in vivo. *Cell Transplant*. 2012;21(4):723-737.

113. Bolte J, Reich DM, Hau S, et al. Assessment of neuroprotective effects of human umbilical cord blood mononuclear cell subpopulations in vitro and in vivo. *Cell Transplant*. 2012;21(4):723-737.

114. Messina B, Papek PV. Immunomodulators and microRNAs as neurorestorative therapy for ischemic stroke. *Neural Regen Res*. 2017;12(6):865-874.

115. Tseng N, Lambie SC, Huynh CQ, et al. Mitochondrial transfer from bone marrow-derived ALD-401 cells in patients with recent stable ischemic stroke (RECOVER-Stroke). *Eur J Med Res*. 2019;86(1):5-16.

116. Hess DC, Wechsler LR, Clark WM, et al. Safety and efficacy of human umbilical cord blood mononuclear cell transplantation following experimental stroke in rats. *Cell Transplant*. 2012;21(6):1199-1211.

117. Bonsack B, Corey S, Shear A, et al. The cerebral embolism evoked multiple organ dysfunction syndrome (MODS): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Neurol*. 2017;16(5):360-368.

118. Stenzel-Poore MP, Stevens SL, Xiong Z, et al. Effect of ischemic preconditioning on genomic response to cerebral ischemia: similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states. *Lancet*. 2003;362(9389):1028-1037.

119. Chong J, Bulluck H, Kwok W, et al. Chronic remote ischemic conditioning for cardiovascular protection. *Circ Res*. 2016;119(5):541-553.

120. Janowski M, Wagner DC, Bolte J. Stem cell-based tissue replacement after stroke: factual necessity or notorious fiction? *Stroke*. 2015;46(8):2354-2363.

121. Kikuchi-Taura A, Okinaka Y, Takeuchi Y, et al. Bone marrow mononuclear cells activate angiogenesis via gap junction-mediated cell-cell interaction. *Stroke*. 2020;51(4):1279-1289.

122. Bronckaers A, Hilkens P, Martens W, et al. Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerated angiogenesis. *Pharmacol Ther*. 2014;143(2):181-196.

123. Bolte J, Reich DM, Hau S, et al. Assessment of neuroprotective effects of human umbilical cord blood mononuclear cell subpopulations in vitro and in vivo. *Cell Transplant*. 2012;21(4):723-737.

124. Bao X, Wei J, Feng M, et al. Transplantation of human bone marrow-derived mesenchymal stem cells promotes behavioral recovery and endogenous neurogenesis after cerebral ischemia in rats. *Brain Res*. 2011;1367:103-113.

125. Neal EG, Acosta SA, Kaneko Y, Ji X, Borlongan CV. Regulatory T-cells within bone marrow-derived stem cells actively confer immunomodulatory and neuroprotective effects against stroke. *J Cereb Blood Flow Metab*. 2019;39(9):1750-1758.

126. Martinez B, Papek PV. Immunomodulators and microRNAs as neurorestorative therapy for ischemic stroke. *Neural Regen Res*. 2017;12(6):865-874.

127. Sun Z, Gu L, Wu K, et al. VX-765 enhances autophagy of human umbilical cord mesenchymal stem cells against stroke-induced apoptosis and inflammatory responses via AMPK/mTOR signaling pathway. *CNS Neurosci Ther*. 2020;26(9):952-961.

128. Bolte J, Schmidt UR, Reich DM, et al. Determination of the therapeutic time window for human umbilical cord blood mononuclear cell transplantation following experimental stroke in rats. *Cell Transplant*. 2012;21(6):1199-1211.

129. Yang B, Parsha K, Schaar K, et al. Cryopreservation of bone marrow mononuclear cells alters their viability and suppression composition but not their treatment effects in a rodent stroke model. *Stem Cells Int*. 2016;2016:5876836.

130. Ramirez FD, Motazedian P, Jung RG, et al. Methodological rigor in preclinical cardiovascular studies: targets to enhance reproducibility and promote research translation. *Circ Res*. 2017;120(12):1916-1926.

131. Cui LL, Golubczyk D, Tolpanam AM, Bolte J, Jolkkonen J. Cell therapy for ischemic stroke: are differences in preclinical and clinical study design responsible for the translational loss of efficacy? *Ann Neurol*. 2019;86(1):5-16.

132. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intralesional stem cell delivery: the pulmonary first-pass effect. *Stem Cells Dev*. 2009;18(5):683-692.

133. Cui LL, Kerkela E, Bakreen A, et al. The cerebral embolism evoked multiple organ dysfunction syndrome (MODS): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Neurol*. 2017;16(5):360-368.

134. Cui LL, Kerkela E, Bakreen A, et al. The cerebral embolism evoked multiple organ dysfunction syndrome (MODS): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Neurol*. 2017;16(5):360-368.

135. Chen J, Chopp M. Exosome therapy for stroke. *Stroke*. 2018;49(5):1083-1090.

136. Chong J, Bulluck H, Kwok W, et al. Bone marrow mononuclear cells activate angiogenesis via gap junction-mediated cell-cell interaction. *Stroke*. 2020;51(4):1279-1289.
141. Han D, Sun M, He PP, Wen LL, Zhang H, Feng J. Ischemic post-conditioning alleviates brain edema after focal cerebral ischemia reperfusion in rats through down-regulation of aquaporin-4. J Mol Neurosci. 2015;56(3):722-729.

142. Li J, Hu XS, Zhou FF, et al. Limb remote ischemic postconditioning protects integrity of the blood-brain barrier after stroke. Neural Regen Res. 2018;13(9):1585-1593.

143. Cheng Z, Li L, Mo X, et al. Non-invasive remote limb ischemic postconditioning protects rats against focal cerebral ischemia by upregulating STAT3 and reducing apoptosis. Int J Mol Med. 2014;34(4):957-966.

144. Doepnner TR, Zechmeister B, Kaltwasser B, et al. Very delayed remote ischemic preconditioning induces sustained neurological recovery by mechanisms involving enhanced angionoeugenesis and peripheral immunosuppression reversal. Front Cell Neurosci. 2018;12:383.

145. Esmaeeli-Nadimi A, Kennedy D, Allahavakoli M. Opening the window: Ischemic postconditioning reduces the hyperemic response of delayed tissue plasminogen activator and extends its therapeutic time window in an embolic stroke model. Eur J Pharmacol. 2015;764:55-62.

146. Blauenfeldt RA, Hjort N, Gude MF, et al. A multicentre, randomised, sham-controlled trial on REMote iSchemic conditioning In patients with acute StROKE (RESIST) - Rationale and study design. Eur Stroke J. 2020;5(1):94-101.

147. Guo L, Zhou D, Wu D, et al. Short-term remote ischemic conditioning may protect monkeys after ischemic stroke. Ann Clin Transl Neurol. 2019;6(2):310-323.

148. Hansen LF, Nielsen NSK, Christoffersen LC, Kruuse C. Translational challenges of remote ischemic conditioning in ischemic stroke - a systematic review. Ann Clin Transl Neurol. 2021;8(8):1720-1729.

149. Zheng S, Zuo Z. Isoflurane preconditioning induces neuroprotection against ischemia via activation of P38 mitogen-activated protein kinases. Mol Pharmacol. 2004;65(5):1172-1180.

150. Xiong L, Zheng Y, Wu M, et al. Preconditioning with isoflurane produces dose-dependent neuroprotection via activation of adenosine triphosphate-regulated potassium channels after focal cerebral ischemia in rats. Anesth Analg. 2003;96(1):233-237. table of contents.

151. Gray JJ, Bickler PE, Fahmlan CS, Zhan X, Schuyler JA. Isoflurane neuroprotection in hypoxic hippocampal slice cultures involves increases in intracellular Ca2+ and mitogen-activated protein kinases. Anesthesiology. 2005;102(3):606-615.

152. Ghuman H, Matta R, Tompkins A, et al. ECM hydrogel improves the delivery of PEG microsphere-encapsulated neural stem cells and endothelial cells into tissue cavities caused by stroke. Brain Res Bull. 2021;168:120-137.

153. Boltze J, Modo MM, Mays RW, et al. Stem cells as an emerging paradigm in stroke 4: advancing and accelerating preclinical research. Stroke. 2019;50(11):3299-3306.

154. Stein I. Waterhouse-Friderichsen syndrome complicated by acute pericarditis, with recovery. N Y State J Med. 1947;47(13):1507.

155. Shahrestani S, Wishart D, Han SMJ, et al. A systematic review of next-generation point-of-care stroke diagnostic technologies. Neurosurg Focus. 2021;51(1):E11.

156. van Meenen LCC, van Stigt MN, Marquering HA, et al. Detection of large vessel occlusion stroke with electroencephalography in the emergency room: first results of the ELECTRA-STROKE study. J Neuro. 2021;1-9. doi: 10.1007/s00415-021-10781-6. Epub ahead of print.

157. Duarte-Gamas L, Pereira-Neves A, Sousa J, Sousa-Pinto B, Rocha-Neves J. The diagnostic accuracy of intra-operative near infrared spectroscopy in carotid artery endarterectomy under regional anaesthesia: systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2021;62(4):522-531.

158. Erdoes G, Rummel C, Basciani RM, et al. Limitations of current near-infrared spectroscopy configuration in detecting focal cerebral ischemia during cardiac surgery: an observational case-series study. Artif Organs. 2018;42(10):1001-1009.

159. Thorpe SG, Thibeault CM, Wilk SJ, et al. Velocity curvature index: a novel diagnostic biomarker for large vessel occlusion. Transl Stroke Res. 2019;10(5):475-484.

160. Kellner CR, Sauvageau E, Snyder KV, et al. The VITAL study and overall pooled analysis with the ViP3 non-invasive stroke detection device. J Neurointerv Surg. 2018;10(11):1079-1084.

161. Tian F, Bibi F, Dale N, Imray CHE. Blood purine measurements as a rapid real-time indicator of reversible brain ischaemia. Purinergic Signal. 2017;13(4):521-528.

162. Lan XY, Sun ZW, Xu GL, et al. Bone marrow mesenchymal stem cells exert protective effects after ischemic stroke through up-regulation of glutathione. Stem Cell Res Rep. 2021. doi: 10.1007/ s12015-021-10178-y. Epub ahead of print.

163. Gaude E, Nogueira B, Ladreda Mochales M, et al. A novel combination of blood biomarkers and clinical stroke scales facilitates detection of large vessel occlusion ischemic strokes. Diagnostics (Basel). 2021;11(7):1137.

164. Da Silva-Candal A, Dopico-Lopez A, Perez-Mato M, et al. Characterization of a temporal profile of biomarkers as an index for ischemic stroke onset definition. J Clin Med. 2021;10(14):3136.

165. Tiedt S, Brandmaier S, Kollmeier H, et al. Circulating metabolites differentiate acute ischemic stroke from stroke mimics. Ann Neurol. 2020;88(4):736-746.

How to cite this article: Jin X, Li P, Michalski D, et al. Perioperative stroke: A perspective on challenges and opportunities for experimental treatment and diagnostic strategies. CNS Neurosci Ther. 2022;28:497-509. doi: 10.1111/cns.13816.